---
layout: default
title: Anas Platyrhynchos Feather Anser Anser Feather Ars
parent: 僅模型預測 (L5)
nav_order: 315
evidence_level: L5
indication_count: 0
---

# Anas Platyrhynchos Feather Anser Anser Feather Ars
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Allergen Homeopathic Complex: Insufficient Data for TxGNN Drug Repurposing Evaluation

## One-Sentence Summary

This submission is a complex multi-component preparation containing 17 ingredients — primarily animal-derived allergens (feathers, hair, dander, skin) combined with classical homeopathic substances (Arsenicum trioxide, Phosphorus, Strychnos nux-vomica seed). The TxGNN pipeline was unable to generate any repurposing predictions for this compound, as it currently has no DrugBank ID, no registered indications, and is not marketed in Taiwan. Without a mapped drug identity and target indication, a drug repurposing evaluation cannot be completed.

---

## Quick Overview

| Item | Content |
|------|---------|
| Drug Components | 17-ingredient allergen + homeopathic complex |
| Original Indication | None recorded |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (model prediction only — in this case, no prediction generated) |
| Taiwan Market Status | Not marketed |
| Number of approvals | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Was Generated

The TxGNN model requires a valid DrugBank ID to map a drug into the biomedical knowledge graph and generate repurposing candidates. This preparation has several characteristics that prevent pipeline execution:

1. **No DrugBank ID**: The drug could not be mapped to any single node in the knowledge graph. The 17-ingredient string does not correspond to a registered single-entity drug in DrugBank.

2. **Compound identity is ambiguous**: The ingredient list includes both biological allergens (animal dander, feathers, hair) and classical homeopathic substances (Arsenicum album / arsenic trioxide, Phosphorus, Nux vomica). This mixture pattern is characteristic of homeopathic desensitization products, which are not classified or modeled as conventional pharmacological agents in TxGNN's training data.

3. **No approved indication on file**: Without a known therapeutic anchor, the biological plausibility analysis — which compares mechanism-to-disease similarity between original and predicted indications — cannot be performed.

---

## Components Identified

For transparency, the 17 listed ingredients are categorized below:

**Animal Allergen Sources (14 components)**

| Component | Source | Allergen Type |
|-----------|--------|---------------|
| Anas platyrhynchos feather | Mallard duck | Avian feather |
| Anser anser feather | Domestic goose | Avian feather |
| Gallus gallus feather | Chicken | Avian feather |
| Serinus canaria feather | Canary | Avian feather |
| Bos taurus hair | Cattle | Mammal hair |
| Canis lupus familiaris hair | Dog | Mammal hair |
| Cavia porcellus hair | Guinea pig | Mammal hair |
| Felis catus hair | Cat | Mammal hair |
| Mesocricetus auratus skin | Hamster | Mammal skin |
| Mus musculus hair | House mouse | Mammal hair |
| Oryctolagus cuniculus hair | Rabbit | Mammal hair |
| Rattus norvegicus hair | Norway rat | Mammal hair |
| Sus scrofa hair | Domestic pig | Mammal hair |
| Equus caballus dander | Horse | Mammal dander |

**Homeopathic/Chemical Substances (3 components)**

| Component | Common Name | Notes |
|-----------|------------|-------|
| Arsenic trioxide | Arsenicum album | Classical homeopathic remedy; also a registered anticancer agent (Trisenox) at pharmacological doses |
| Phosphorus | Phosphorus | Classical homeopathic mineral remedy |
| Strychnos nux-vomica seed | Nux vomica | Classical homeopathic plant remedy; contains strychnine |

> **Note on Arsenic Trioxide**: At pharmacological (non-homeopathic) doses, arsenic trioxide is an FDA-approved treatment for acute promyelocytic leukemia (APL). However, in a homeopathic formulation, the active substance is diluted to sub-pharmacological concentrations, and the drug repurposing framework applicable to Trisenox would not apply here.

---

## Taiwan Market Status

This compound has **0 TFDA licenses** and is currently not marketed in Taiwan. No approval records were returned in the regulatory query.

---

## Safety Considerations

Because this product contains **Arsenic trioxide** and **Strychnos nux-vomica seed (strychnine precursor)** as listed components, the following general cautions apply regardless of formulation level:

- **Arsenic trioxide** at pharmacological doses carries Black Box Warnings for QT prolongation, electrolyte abnormalities, and APL differentiation syndrome. Dose and formulation context determine actual risk.
- **Strychnos nux-vomica** contains strychnine, a potent convulsant alkaloid. Homeopathic dilutions are generally considered below toxicity thresholds, but formulation concentration is not confirmed in this data pack.

Please refer to the package insert (if available) for full safety information specific to this preparation's intended dose and route.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This submission cannot be evaluated by the TxGNN drug repurposing pipeline in its current form. The product is a multi-allergen homeopathic complex without a DrugBank-mapped drug identity, no approved indication anchor, and no TxGNN predictions were generated. A meaningful repurposing report requires a single pharmacologically active entity with a known mechanism of action.

**To proceed, the following is needed:**

- **Clarify therapeutic intent**: Is this product intended as a homeopathic allergy desensitization product, an allergen skin-testing panel, or a conventional pharmacological agent? The answer determines which evaluation framework applies.
- **Obtain product monograph / package insert**: Confirm approved indication, concentration of each component, and route of administration — especially critical given the presence of arsenic trioxide and strychnine-containing ingredients.
- **If arsenic trioxide is the pharmacologically active component**: Re-submit with arsenic trioxide (DrugBank ID: DB01169) as the primary drug entity. That evaluation can be conducted independently using the existing TxGNN pipeline.
- **If this is an allergen immunotherapy product**: A drug repurposing framework is not applicable. Regulatory assessment under allergen immunotherapy guidelines (e.g., FDA CBER pathway) would be more appropriate.
- **Resolve DrugBank mapping**: Determine whether any single component can serve as the primary active substance for knowledge graph embedding.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

